IP Library › Granted Patent US 11,306,305
Granted Patent B2
US 11,306,305 · App. 16/327,605 · Granted Apr 19, 2022

Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions

Inventors: Keith Gagnon (Carbondale, IL); Masad Damha (Montreal, CA); Elise Malek-Adamian (Ottawa, CA); Maryam Habibian (Montreal, CA); Daniel Timothy O'Reilly (Waterlooville, GB); Zachery Kartje (Valparaiso, IN)
Assignee: Board of Trustees of Southern Illinois University
C12N15/102A61K48/00C12N9/22C12N15/11C12N15/113C12N15/90C12N15/907C12N2310/20C12N2310/315C12N2310/318C12N2310/319C12N2310/3231C12N2310/344C12N2310/346C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,306,305
App. No.
16/327,605
Granted
Apr 19, 2022
Kind
B2
Abstract

The present disclosure provides CRISPR/Cas9 ribonucleoprotein compositions comprising chemically modified CRISPR RNA (crRNA) guide and trans-acting CRISPR RNA (tracrRNA) components. Methods of using the disclosed CRISPR/Cas9 ribonucleoprotein compositions are also provided.

Claims (14)

1. A composition comprising a Cas9 protein, a first oligonucleotide comprising a first region having a 5′ end and a 3′ end and a second region, and a second oligonucleotide comprising a first region and a second region, wherein said second region of said first oligonucleotide interacts with said first region of said second oligonucleotide, and said second region of said second oligonucleotide interacts with said Cas9 protein, wherein all nucleotides of said first oligonucleotide are 2′-deoxyribonucleotides or 2′-deoxyribonucleotide analogs.

2. The composition of claim 1 , wherein said first oligonucleotide comprises the chemical structure of crRNA_K.

3. The composition of claim 1 , wherein said first oligonucleotide comprises at least a first 2′-fluoroarabinonucleotide.

4. The composition of claim 1 , wherein said Cas9 protein comprises at least a first mutation that inactivates said Cas9 protein.

5. The composition of claim 4 , wherein said Cas9 protein comprises a D10A or a H840A mutation.

6. The composition of claim 5 , wherein said Cas9 protein comprises a D10A and a H840A mutation.

7. A method of binding a double-stranded DNA without cleaving said double-stranded DNA, comprising contacting said double-stranded DNA with the composition of claim 1 .

8. The method of claim 7 , wherein said first oligonucleotide comprises at least a first 2′-fluoroarabinonucleotide.

9. A method of inhibiting transcription of a double-stranded DNA, comprising contacting said double-stranded DNA with the composition of claim 1 .

10. The method of claim 9 , wherein said first oligonucleotide comprises at least a first 2′-fluoroarabinonucleotide.

11. The method of claim 9 , wherein said double-stranded DNA is located in a cell.

12. A method of activating transcription of a double-stranded DNA, comprising contacting said double-stranded DNA with the composition of claim 1 .

13. The method of claim 12 , wherein said first oligonucleotide comprises at least a first 2′-fluoroarabinonucleotide.

14. The method of claim 12 , wherein said double-stranded DNA is located in a cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2019
From: GAGNON, KEITH; DAMHA, MASAD; MALEK-ADAMIAN, ELISE; HABIBIAN, MARYAM; O'REILLY, DANIEL TIMOTHY; KARTJE, ZACHERY
To: BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY; THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
Reel/Frame 048412/0800 →
Continuity (2)
Provisional Application 62398775 · Sep 23, 2016
Related Publication 20190185844A1 · Jun 20, 2019
Cited By (1)
US 12,390,538